Related references
Note: Only part of the references are listed.Patent-related survey on new monoamine oxidase inhibitors and their therapeutic potential
Simone Carradori et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2012)
Rosiglitazone Does Not Improve Cognition or Global Function when Used as Adjunctive Therapy to AChE Inhibitors in Mild-to-Moderate Alzheimer's Disease: Two Phase 3 Studies
C. Harrington et al.
CURRENT ALZHEIMER RESEARCH (2011)
Combination Treatment in Alzheimers Disease: Results of a Randomized, Controlled Trial with Cerebrolysin and Donepezil
X. A. Alvarez et al.
Current Alzheimer Research (2011)
Lights and Shadows on Monoamine Oxidase Inhibition in Neuroprotective Pharmacological Therapies
Claudia Binda et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2011)
Combination Therapy for Alzheimerʼs Disease
Laxeshkumar Patel et al.
DRUGS & AGING (2011)
The economic impact of dementia in Europe in 2008-cost estimates from the Eurocode project
A. Wimo et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2011)
Synthesis, Biological Evaluation, and Molecular Modeling of Donepezil and N-[(5-(Benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine Hybrids as New Multipotent Cholinesterase/Monoamine Oxidase Inhibitors for the Treatment of Alzheimer's Disease
Irene Bolea et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Additive effects of a cholinesterase inhibitor and a histamine inverse agonist on scopolamine deficits in humans
William Cho et al.
PSYCHOPHARMACOLOGY (2011)
Alzheimer's disease - input of vitamin D with mEmantine assay (AD-IDEA trial): study protocol for a randomized controlled trial
Cedric Annweiler et al.
TRIALS (2011)
Site-Activated Chelators Targeting Acetylcholinesterase and Monoamine Oxidase for Alzheimer's Therapy
Hailin Zheng et al.
ACS CHEMICAL BIOLOGY (2010)
Novel Huprine Derivatives with Inhibitory Activity toward β-Amyloid Aggregation and Formation as Disease-Modifying Anti-Alzheimer Drug Candidates
Elisabet Viayna et al.
CHEMMEDCHEM (2010)
Depression and Alzheimer's disease: Neurobiological links and common pharmacological targets
Filippo Caraci et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2010)
Amyloid-β-Acetylcholinesterase complexes potentiate neurodegenerative changes induced by the Aβ peptide. Implications for the pathogenesis of Alzheimer's disease
Margarita C. Dinamarca et al.
MOLECULAR NEURODEGENERATION (2010)
The Alzheimer's disease mitochondrial cascade hypothesis: An update
Russell H. Swerdlow et al.
EXPERIMENTAL NEUROLOGY (2009)
Site-Activated Multifunctional Chelator with Acetylcholinesterase and Neuroprotective-Neurorestorative Moieties for Alzheimer's Therapy
Hailin Zheng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
PF9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] confers MAO-B independent neuroprotection in ER stress-induced cell death
Elisenda Sanz et al.
MOLECULAR AND CELLULAR NEUROSCIENCE (2009)
Memoquin: A Multi-Target-Directed Ligand as an Innovative Therapeutic Opportunity for Alzheimer's Disease
Maria Laura Bolognesi et al.
NEUROTHERAPEUTICS (2009)
Oxidative stress in Alzheimer disease
Alejandro Gella et al.
CELL ADHESION & MIGRATION (2009)
Increased neurofibrillary tangles in patients with Alzheimer disease with comorbid depression
Michael A. Rapp et al.
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY (2008)
Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta (25-35)
Hiroko Tsunekawa et al.
BEHAVIOURAL BRAIN RESEARCH (2008)
Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators
Tamar Amit et al.
FASEB JOURNAL (2008)
The frequency of cognitive impairment in patients with anxiety, depression, and bipolar disorder: An unaccounted source of variance in clinical trials
C. Thomas Gualtieri et al.
JOURNAL OF CLINICAL PSYCHIATRY (2008)
Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates
Lei Fang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Multi-target-directed ligands to combat neurodegenerative diseases
Andrea Cavalli et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Anti-apoptotic effect of Mao-B inhibitor PF9601N[N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] is mediated by p53 pathway inhibition in MPP+-treated SH-SY5Y human dopaminergic cells
Elisenda Sanz et al.
JOURNAL OF NEUROCHEMISTRY (2008)
Neuropsychiatric symptoms in dementia: Importance and treatment considerations
Clive Ballard et al.
INTERNATIONAL REVIEW OF PSYCHIATRY (2008)
First Gallamine-Tacrine hybrid:: Design and characterization at cholinesterases and the M2 muscarinic receptor
Paul W. Elsinghorst et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease
Yael Avramovich-Tirosh et al.
JOURNAL OF NEUROCHEMISTRY (2007)
Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease
Jack J. Chen et al.
CLINICAL THERAPEUTICS (2007)
CYP-dependent metabolism of PF9601N, a new monoamine oxidase-B inhibitor, by C57BL/6 mouse and human liver microsomes
Stefania Dragoni et al.
JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES (2007)
Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; Ladostigil
Moussa B. H. Youdim et al.
NEUROTOXICITY RESEARCH (2006)
Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases
Cornelis J. Van der Schyf et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2006)
Protective effect of N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine (PF9601N) on mitochondrial permeability transition
V. Battaglia et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2006)
Design and synthesis of N-benzylpiperidine-purine derivatives as new dual inhibitors of acetyl- and butyryleholinesterase
MI Rodríguez-Franco et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2005)
Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent
NH Greig et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases:: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition
H Zheng et al.
JOURNAL OF NEUROCHEMISTRY (2005)
Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion
S Gal et al.
JOURNAL OF NEUROCHEMISTRY (2005)
CNS targets for multi-functional drugs in the treatment of Alzheimers and Parkinsons diseases
MBH Youdim et al.
JOURNAL OF NEURAL TRANSMISSION (2005)
Biochemical and molecular studies of NMDA receptor subunits NR1/2A/2B in hippocampal subregions throughout progression of Alzheimer's disease pathology
AJ Mishizen-Eberz et al.
NEUROBIOLOGY OF DISEASE (2004)
Monoamine oxidases: Certainties and uncertainties
KF Tipton et al.
CURRENT MEDICINAL CHEMISTRY (2004)
Monoamine oxidase-B inhibition in Alzheimer's disease
P Riederer et al.
NEUROTOXICOLOGY (2004)
Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: Role in neurodegenerative diseases
WJ Burke et al.
NEUROTOXICOLOGY (2004)
Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases
MBH Youdim et al.
JOURNAL OF NEURAL TRANSMISSION (2004)
Prazosin-related compounds.: Effect of transforming the piperazinylquinazoline moiety into an aminomethyltetrahydroacridine system on the affinity for α1-adrenoreceptors
M Rosini et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor
Y Sagi et al.
JOURNAL OF NEUROCHEMISTRY (2003)
A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease
M Weinstock et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2003)
Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B
W Tatton et al.
JOURNAL OF NEURAL TRANSMISSION (2003)
Protective effect of N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine (PF 9601N), a novel MAO-B inhibitor, on dopamine-lesioned PC12 cultured cells
V Perez et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2003)
PF9601N[N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine], a new MAO-B inhibitor, attenuates MPTP-induced depletion of striatal dopamine levels in C57/BL6 mice
V Perez et al.
NEUROCHEMISTRY INTERNATIONAL (2003)
Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease
J Sterling et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
Neuroprotective effect of the monoamine oxidase inhibitor PF9601N[N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] on rat nigral neurons after 6-hydroxydopamine-striatal lesion
B Cutillas et al.
NEUROSCIENCE LETTERS (2002)
Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-3R)aminoindan-5-YL)-ethyl methyl carbamate
MBH Youdim et al.
CELLULAR AND MOLECULAR NEUROBIOLOGY (2001)
A structural motif of acetylcholinesterase that promotes amyloid β-peptide fibril formation
GV De Ferrari et al.
BIOCHEMISTRY (2001)
New insights on how metals disrupt amyloid β-aggregation and their effects on amyloid-β cytotoxicity
Y Yoshiike et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria
BS Kristal et al.
FREE RADICAL BIOLOGY AND MEDICINE (2001)
Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat
MC Carrillo et al.
LIFE SCIENCES (2000)
3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells
I Lamensdorf et al.
BRAIN RESEARCH (2000)
How important is oxidative damage? Lessons from Alzheimer's disease
G Perry et al.
FREE RADICAL BIOLOGY AND MEDICINE (2000)
The novel type B MAO inhibitor PF9601N enhances the duration of L-DOPA-induced contralateral turning in 6-hydroxydopamine lesioned rats
G Prat et al.
JOURNAL OF NEURAL TRANSMISSION (2000)
Monoamine oxidase-B inhibitors in the treatment of Alzheimers disease
T Thomas
NEUROBIOLOGY OF AGING (2000)
Share Paper
